The BioCanRx network is changing the face of cancer treatment
BioCanRx’s vision is to cure patients and enhance the quality of life of those living with cancer. We will do this by supporting world-class research in the area of immune oncology, and by accelerating to the clinic the most promising cancer immunotherapies designed to save lives and enable a better quality of life. Through an innovative, collaborative funding process BioCanRx is becoming a world-leader in the translation, manufacture and adoption of leading edge cancer immunotherapy treatments for the benefit of cancer patients.
Diving Deep into the Abdominal Cavity
Dr. Rebecca Auer holds a Catalyst Grant from BioCanRx to test the use of immunotherapy to treat peritoneal carcinomatosis. Her work on this project is intended to get the evidence needed to proceed to clinical trials and, she says, it’s looking promising.
John Bell Wins Inaugural ESGCT Public and Patient Engagement Award
BioCanRx is pleased to announce that Scientific Director Dr. John Bell has won the the inaugural European Society for Gene and Cell Therapy (ESGCT) Public and Patient Engagement Award.
BioCanRx Cycle II LOI Call
BioCanRx recently announced a Call for Letters of Intent. Selected Letters of Intent will be featured in the Scientific Program of our Cycle II application to the federal government’s Networks of Centres of Excellence (NCE) Program. The deadline for applications is May 1st, 2019.
